OncoMatch/Clinical Trials/NCT06162650
Total Neoadjuvant Therapy in Rectal Cancer
Is NCT06162650 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies mFOLFOX6 for rectal cancer.
Treatment: mFOLFOX6 — In this phase 2 study, the efficacy of total neoadjuvant therapy in Taiwanese patients with rectal cancer will be investigated. Patients with stage II or III middle/low rectal cancer will be prospective enrolled. The total neoadjuvant therapy with the short-course radiotherapy (5×5 Gy over a maximum of 8 days) followed by chemotherapy with mFOLFOX6 for 9 cycles will be administered. The primary endpoint is the complete response (CR) rate which will take into account the patients with clinical and pathological complete response.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No prior chemotherapy, radiotherapy or surgery for rectal cancer
Cannot have received: radiotherapy
No prior chemotherapy, radiotherapy or surgery for rectal cancer
Cannot have received: surgery
No prior chemotherapy, radiotherapy or surgery for rectal cancer
Cannot have received: pelvic radiotherapy
Patients who have received prior pelvic radiotherapy
Lab requirements
Blood counts
anc ≥1,500/μl; hb ≥8.0 gm/dl; platelet 100,000/mm3
Kidney function
creatinine ≤1.5x upper normal limit
Liver function
total bilirubin ≤1.5x upper normal limit; ast ≤3x upper normal limit; alt ≤3x upper normal limit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify